Literature DB >> 833607

Central deopaminergic receptor supersensitivity and its relevance to Parkinson's disease.

C J Pycock, C D Marsden.   

Abstract

The degeneration of the substantia nigra that characterises Parkinson's disease may cause an alteration in sensitivity of striatal dopamine receptors. The development of denervation supersensitivity has been held to be responsible for some of the effects of chronic levodopa therapy. The rotating rodent is an animal model commonly used to study the phenomenon of striatal dopamine receptor supersensitivity, and to investigate drugs which may prove to be beneficial in the treatment of Parkinson's disease. We have investigated as to whether long-term oral administration of levodopa to mice with unilateral destruction of striatal dopaminergic nerve terminals influences dopaminergic receptor denervation supersensitivity as judged by the circling response following systemically administered levodopa. It does not do so and the relevance of these findings to the treatment of Parkinson's disease is discussed.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 833607     DOI: 10.1016/0022-510x(77)90009-0

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  8 in total

1.  L-dopa causes an acute, partial and reversible reversal of denervation-induced supersensitivity of striatal dopaminergic receptors.

Authors:  S Ferre; M Casas; A Cobos; C Garcia; F Jane; J M Grau
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

2.  A conditioned anti-parkinsonian drug effect in the hemi-parkinsonian rat.

Authors:  R J Carey
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

3.  Presynaptic dopaminergic compartment determines the susceptibility to L-DOPA-induced dyskinesia in rats.

Authors:  Ayse Ulusoy; Gurdal Sahin; Deniz Kirik
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-06       Impact factor: 11.205

4.  The effects of acute levodopa withdrawal on motor performance and dopaminergic receptor sensitivity in patients with Parkinson's disease.

Authors:  N Turjanski; W Fernandez; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-07       Impact factor: 10.154

5.  Dopamine receptors and sleep induction in man.

Authors:  S Bassi; M G Albizzati; L Frattola; D Passerini; M Trabucchi
Journal:  J Neurol Neurosurg Psychiatry       Date:  1979-05       Impact factor: 10.154

6.  Long-term treatment of Parkinson's disease with bromocriptine.

Authors:  A Rascol; B Guiraud; J L Montastruc; J David; M Clanet
Journal:  J Neurol Neurosurg Psychiatry       Date:  1979-02       Impact factor: 10.154

7.  The comparative long-term effects of ciladopa (AY-27,110), a chemically novel dopaminergic agonist, in 6-OHDA-lesioned and intact rats.

Authors:  K Voith
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

8.  Differential action of bromocriptine on nigrostriatal versus mesolimbic dopaminergic neurons.

Authors:  A C Barton; K E Moore; K T Demarest
Journal:  J Neural Transm       Date:  1987       Impact factor: 3.575

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.